Baseline characteristics of patients with complete response
| Characteristic . | Proportion of tipifarnib patients with CR (%) . |
|---|---|
| Age, y | |
| Less than 75 | 7/92 (8) |
| 75 or more | 11/136 (8) |
| AML with myelodysplasia | |
| Yes | 8/90 (9) |
| No | 10/138 (7) |
| Unfavorable cytogenetics | |
| Yes | 3/68 (4) |
| No | 12/123 (10) |
| Not done | 3/37 (8) |
| ECOG performance status | |
| 0 | 5/46 (11) |
| 1 | 9/119 (8) |
| 2 | 4/63 (6) |
| Baseline blasts in marrow, range | 21%-98% |
| Characteristic . | Proportion of tipifarnib patients with CR (%) . |
|---|---|
| Age, y | |
| Less than 75 | 7/92 (8) |
| 75 or more | 11/136 (8) |
| AML with myelodysplasia | |
| Yes | 8/90 (9) |
| No | 10/138 (7) |
| Unfavorable cytogenetics | |
| Yes | 3/68 (4) |
| No | 12/123 (10) |
| Not done | 3/37 (8) |
| ECOG performance status | |
| 0 | 5/46 (11) |
| 1 | 9/119 (8) |
| 2 | 4/63 (6) |
| Baseline blasts in marrow, range | 21%-98% |